Citizens Initiates Coverage of Opus Genetics (IRD)

Opus Genetics, Inc. (NASDAQ:IRD) is one of the best performing small cap stocks so far in 2026. On April 28, Citizens initiated coverage of Opus Genetics, Inc. (NASDAQ:IRD) with an Outperform rating, setting a price target of $12. The firm told investors in a research note that the company is in the process of developing a portfolio of AAV-based gene therapies for inherited retinal diseases, aimed at preserving and/or restoring vision in patients who lack any treatments today. Citizens believes that Opus Genetics, Inc.’s (NASDAQ:IRD) inherited retinal disease focus provides several benefits for a large commercial opportunity.

In a separate development, Opus Genetics, Inc. (NASDAQ:IRD) announced on April 6 a strategic financing agreement with Oberland Capital Management LLC to accelerate the clinical development, manufacturing, and potential commercialization of its broad gene therapy pipeline to maximize shareholder value. Management reported that the new note facility provides the company with access to future non-dilutive funding of up to $155 million to support its future strategic initiatives and growth. It added that an initial tranche of $35 million would be funded at the initial closing, and a second $35 million tranche would be available at the company’s option within the next twelve months. Additional tranches up to $35 million would also be available to Opus Genetics, Inc. (NASDAQ:IRD) upon the occurrence of certain milestones.

Opus Genetics, Inc. (NASDAQ:IRD) is involved in the research and development of ophthalmic biopharmaceutical products, with a focus on the development and commercialization of therapies for the treatment of several eye disorders.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.